Physician profile
David L Cooley
NPI 1528025871
$4,885.10
in general payments reported to CMS, 2019-2025
36 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $308 · 2021: $803 · 2022: $1,058 · 2023: $671 · 2024: $613 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $493.06 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $477.84 | 2019-2025 | Vraylar |
| Sanofi-Aventis U.S. LLC | $432.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $418.90 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $406.67 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $361.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.33 | 2019-2025 | Jardiance |
| Pfizer INC. | $263.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $260.14 | 2019-2024 | Xarelto |
| Amgen INC. | $215.40 | 2019-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company Ltd. | $177.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $163.00 | 2019-2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $108.88 | 2022-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $92.58 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $81.50 | 2019-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.